Deep Track Capital IMCR Position
Active7-Fund ConvergenceDeep Track Capital increased their position in Immunocore Holdings plc (IMCR) in Q4 2025, holding $69.6M worth of shares across 2,003,978 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
IMCR is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Brenetafusp in 198 days (Oct 31, 2026), making the timing of Deep Track's position particularly relevant.
Short interest stands at 27.5% of float with 26.4 days to cover, indicating significant bearish positioning against Deep Track's long thesis.
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Full company profile →Short Interest
27.5%
26.4 days to cover
Deep Track Capital IMCR Position History
Frequently Asked Questions
Does Deep Track Capital own IMCR?
Yes. As of Q4 2025, Deep Track Capital holds 2,003,978 shares of Immunocore Holdings plc (IMCR) valued at $69.6M. This data comes from their SEC 13F filing.
How many hedge funds own IMCR?
7 specialist biotech hedge funds currently hold IMCR, including RTW Investments, Rock Springs Capital, Baker Bros. Advisors and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy IMCR?
Deep Track Capital's position in IMCR was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's IMCR position increasing or decreasing?
Deep Track Capital increased their IMCR position in the most recent quarter, adding 203,978 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMCRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →